scispace - formally typeset
Search or ask a question

Showing papers in "Blood in 2002"


Journal ArticleDOI
15 May 2002-Blood
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.

3,127 citations


Journal ArticleDOI
01 Oct 2002-Blood
TL;DR: The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.

2,155 citations


Journal ArticleDOI
01 Feb 2002-Blood
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.

2,000 citations


Journal ArticleDOI
15 Nov 2002-Blood
TL;DR: Possibility for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed, as cancer patients with venous thrombosis are more likely to develop recurrent thromboembolic complications and major bleeding during anticoaggerant treatment than those without malignancy.

1,655 citations


Journal ArticleDOI
15 Jun 2002-Blood
TL;DR: In this paper, the authors analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 acute myelogenous leukemia (AML) patients and found that a high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance.

1,615 citations


Journal ArticleDOI
15 Dec 2002-Blood
TL;DR: In this paper, the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-to-5-year overall survival (OS) of acute myeloid leukemia (AML) patients was investigated.

1,559 citations


Journal ArticleDOI
01 Sep 2002-Blood
TL;DR: Results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene, and preliminary studies suggest that mutantFLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.

1,454 citations


Journal ArticleDOI
01 Nov 2002-Blood
TL;DR: It is suggested that multiple immunological dysfunctions, including cytokine production capability, in addition to functional incompetence of T, B, and NK cells, may lead to the high engraftment levels of xenograft in NOD/SCID/gamma(c)(null) mice.

1,382 citations


Journal ArticleDOI
01 Jan 2002-Blood
TL;DR: In vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy despite dramatic short-term responses in vivo.

1,219 citations


Journal ArticleDOI
15 May 2002-Blood
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.

1,172 citations


Journal ArticleDOI
15 May 2002-Blood
TL;DR: This study is the first to demonstrate that activated, cultured CD4(+)CD25(+) cells can offer substantial protection in a relevant in vivo animal model of disease and have important ramifications for clinical bone marrow and solid organ transplantation.

Journal ArticleDOI
01 Jan 2002-Blood
TL;DR: The results indicate that all of the effects of CSF-1 are mediated via the CSf-1R, but that subtle effects of the CS fms proto-oncogene could result from its CS F-1-independent activation.


Journal ArticleDOI
15 May 2002-Blood
TL;DR: Changes in ferritin are important not only in the classic diseases of iron acquisition, transport, and storage, but also in diseases such as primary hemochromatosis.

Journal ArticleDOI
01 Sep 2002-Blood
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.

Journal ArticleDOI
15 May 2002-Blood
TL;DR: Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.

Journal ArticleDOI
01 Jul 2002-Blood
TL;DR: The most frequent mutation in acute myeloid leukemia (AML) is the FLT3 length mutation (FLT3-LM) as discussed by the authors, which is a molecular marker potentially useful for the characterization of AML.

Journal ArticleDOI
15 Dec 2002-Blood
TL;DR: Risk factor analyses verify previously recognized risk factors (GVHD, receipt of corticosteroids, and neutropenia) and uncover the roles of lymphopenia and viral infections in increasing the incidence of postengraftment IA in the 1990s.

Journal ArticleDOI
15 Dec 2002-Blood
TL;DR: In this article, pre-treatment samples from 224 patients with acute myeloid leukemia (AML) and normal cytogenetics were analyzed for FLT3 internal tandem duplications (ITDs) and Asp835 mutations.

Journal ArticleDOI
15 Aug 2002-Blood
TL;DR: In multivariate analysis, unmutated V(H), 17p deletion, 11q deletion, age, WBC, and LDH were identified as independent prognostic factors, indicating a complementary role of V (H) mutation status and genomic aberrations to predict outcome in CLL.



Journal ArticleDOI
15 Jan 2002-Blood
TL;DR: Comparison of messenger RNA levels for the 3 major multidrug-resistant efflux pumps, MDR1, MRP1, and ABCG2, in bone marrow SP cells reveals that ABCG 2 is the predominant form in these cells.

Journal ArticleDOI
15 Dec 2002-Blood
TL;DR: The poor viability of CD123(-) DCs in vitro was confirmed, but the CD16(+) CD11c(+) DC subset also survived poorly, and these data provide an opportunity to standardize the DC populations used for future molecular, functional and possibly even therapeutic studies.

Journal ArticleDOI
01 Oct 2002-Blood
TL;DR: HLH-94 is very effective, allowing BMT in most patients, and survival of children with HLH has been greatly improved.

Journal ArticleDOI
01 Jun 2002-Blood
TL;DR: Anti-CMV cellular therapy was successful in 5 of 7 patients, whereas in 2 of7 patients, who received an intensified immune suppression at the time of or after T-cell therapy, only transient reductions in virus load were obtained.

Journal ArticleDOI
01 May 2002-Blood
TL;DR: A high frequency of mutations clustered within the ATP-binding region of BCR/ABL in resistant patients is confirmed and may allow intervention before relapse by identifying emerging mutations with defined impacts on imatinib binding.

Journal ArticleDOI
15 Jun 2002-Blood
TL;DR: The mechanism of action of IMiDs against MM cells in vitro is delineated and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM.

Journal ArticleDOI
01 Mar 2002-Blood
TL;DR: Novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM.

Journal ArticleDOI
01 Feb 2002-Blood
TL;DR: CD38 expression is an independent risk factor that can be used with IgV(H) mutations and clinical stage to select patients with B-CLL with the worst prognoses.